Advanced search
Publication Cover
OncoTargets and Therapy Volume 6, 2013 - Issue
Submit an article Journal homepage
59
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer

Mayu OnoDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Tokiko ItoDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Toshiharu KanaiDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Koichi MurayamaDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Hiroshi KoyamaDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Kazuma MaenoDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Yasuhiro MochizukiDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Asumi IesatoDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Toru HanamuraDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Toshihiro OkadaDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
,
Takayuki WatanabeDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, Japan
&
Ken-ichi ItoDivision of Breast and Endocrine Surgery, Department of Surgery (II), Shinshu University School of Medicine, Matsumoto, JapanCorrespondence[email protected]
 show all
Pages 1393-1398 | Published online: 07 Oct 2013

References

  • HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
  • JohnsonDHFehrenbacherLNovotnyWFRandomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200422112184219115169807
  • YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med2003349542743412890841
  • ChenHXMooneyMBoronMPhase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301J Clin Oncol200624213354336016849749
  • KabbinavarFHurwitzHIFehrenbacherLPhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerJ Clin Oncol2003211606512506171
  • ScappaticciFASkillingsJRHoldenSNArterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumabJ Natl Cancer Inst200799161232123917686822
  • MailliezABaldiniCVanJTServentVMalletYBonneterreJNasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patientsBr J Cancer2010103677277520736943
  • CottuPHFourchotteVVincent-SalomonAKriegelIFromantinINecrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapyJ Wound Care2011209403404406408 passim22068139
  • Philippin-LauridantGThureauSOuvrierMJBlotEFatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxelAnn Oncol200819111977197818801882
  • TrainaTANortonLDruckerKSinghBNasal septum perforation in a bevacizumab-treated patient with metastatic breast cancerOncologist200611101070107117110625
  • CabebeEWakeleeHRole of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitorsCurr Treat Options Oncol200781152717634832
  • GiacconeGThe potential of antiangiogenic therapy in non-small cell lung cancerClin Cancer Res20071371961197017404076
  • LazzatiVZygónJLohsiriwatVVeronesiPPetitJYImpaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumabAesthetic Plast Surg201034679679720567970
  • CupponeFBriaEVaccaroVMagnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trialsJ Exp Clin Cancer Res2011305421569417
  • PiergaJYPetitTDelozierTNeoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 studyLancet Oncol201213437538422377126
  • GianniLRomieuGHLichinitserMAVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerJ Clin Oncol201331141719172523569311

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.